Parallel Advisors’s NewAmsterdam Pharma NAMS Stock Holding History

Parallel Advisors’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47.4K	Sell	1,400 -10	-0.7%	-$330	﹤0.01%	2180
2026 Q1	$45.1K	Buy	1,410 +10	+0.7%	+$326	﹤0.01%	2048
2025 Q4	$49.1K	Hold	1,400	–	–	﹤0.01%	1859
2025 Q3	$39.8K	Hold	1,400	–	–	﹤0.01%	1900
2025 Q2	$25.4K	Sell	1,400 -9	-0.6%	-$164	﹤0.01%	2078
2025 Q1	$28.8K	Buy	1,409 +9	+0.6%	+$200	﹤0.01%	1945
2024 Q4	$36K	Hold	1,400	–	–	﹤0.01%	1834
2024 Q3	$23.2K	Buy	1,400 +400	+40%	+$6.92K	﹤0.01%	2012
2024 Q2	$19.2K	Buy	+1,000	New	+$20.1K	﹤0.01%	2016

Other funds holding NAMS

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Parallel Advisors's NAMS Position: Q2 2026 in Review

Parallel Advisors reduced its NewAmsterdam Pharma (NAMS) stake by 0.71% in Q2 2026, selling an estimated $330 and leaving 1,400 shares worth $47.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2180.

Parallel Advisors first reported a position in NAMS in Q2 2024 and has held it in 9 quarters since. The position peaked at $49.1K in Q4 2025. 113 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Parallel Advisors held 1,400 shares of NewAmsterdam Pharma worth $47.4K as of Q2 2026.
Parallel Advisors sold 10 NewAmsterdam Pharma shares in Q2 2026, an estimated $330.
NewAmsterdam Pharma made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2180 holding.
Parallel Advisors first reported a position in NewAmsterdam Pharma in Q2 2024 and has held it in 9 quarters since.
Parallel Advisors's NewAmsterdam Pharma position peaked at $49.1K in Q4 2025.
113 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.